open access

Vol 27, No 3 (2021)
Guidelines / Expert consensus
Get Citation

Guidelines on the prevention and treatment of venous thromboembolism in cancer patients treated surgically, including patients under 18 years of age

Zbigniew Krasiński, Tomasz Urbanek, Anetta Undas, Joanna Rupa-Matysek, Aleksander Araszkiewicz, Katarzyna Derwich, Aneta Klotzka, Artur Antoniewicz, Beata Begier-Krasińska, Cezary Piwkowski, Tomasz Banasiewicz, Marcin Gabriel, Piotr Ładziński, Witold Tomkowski, Dawid Murawa, Rodryg Ramlau, Piotr Rutkowski, Piotr Pruszczyk, Filip M. Szymański, Andrzej Szuba, Tomasz Zubilewicz, Stefan Sajdak, Jerzy Windyga
DOI: 10.5603/AA.2021.0006
·
Acta Angiologica 2021;27(3):81-112.

open access

Vol 27, No 3 (2021)
Requirements

Abstract

Żylna choroba zakrzepowo-zatorow (ŻChZZ), jest jednym z najgroźniejszych powikłań choroby nowotworowej. Terapia przeciwnowotworowa, zabiegi operacyjne czy znacznego stopnia zaawansowanie choroby nowotworowej to tylko niektóre czynniki ryzyka ŻChZZ, stanowiącej nadal jedną z najczęstszych przyczyn zgonu w populacji pacjentów onkologicznych. Duże ryzyko wystąpienia zakrzepicy żył głębokich (ZŻG) oraz ryzyko różnych powikłań, w tym powikłań krwotocznych, pomiędzy poszczególnymi grupami chorych onkologicznych sugeruje przeprowadzenie indywidualnej oceny ryzyka i postępowanie profilaktyczne zależne od sytuacji klinicznej konkretnego pacjenta. Uzasadnia to także stałą aktualizację wytycznych postępowania profilaktycznego proponowanego chorym onkologicznym, czego dowodem jest niniejszy dokument, będący aktualizacją opublikowanych w 2016 wytycznych. W dokumencie zawarto dane opublikowane po 2016 roku i zawiera on najnowsze wskazania dotyczące postępowania profilaktycznego w populacji chorych onkologicznych, ze szczególnym uwzględnieniem profilaktyki przeciwzakrzepowej w dyscyplinach zabiegowych. Został ponadto poszerzony o wskazania dotyczące pacjentów poniżej 18. roku życia.

Abstract

Żylna choroba zakrzepowo-zatorow (ŻChZZ), jest jednym z najgroźniejszych powikłań choroby nowotworowej. Terapia przeciwnowotworowa, zabiegi operacyjne czy znacznego stopnia zaawansowanie choroby nowotworowej to tylko niektóre czynniki ryzyka ŻChZZ, stanowiącej nadal jedną z najczęstszych przyczyn zgonu w populacji pacjentów onkologicznych. Duże ryzyko wystąpienia zakrzepicy żył głębokich (ZŻG) oraz ryzyko różnych powikłań, w tym powikłań krwotocznych, pomiędzy poszczególnymi grupami chorych onkologicznych sugeruje przeprowadzenie indywidualnej oceny ryzyka i postępowanie profilaktyczne zależne od sytuacji klinicznej konkretnego pacjenta. Uzasadnia to także stałą aktualizację wytycznych postępowania profilaktycznego proponowanego chorym onkologicznym, czego dowodem jest niniejszy dokument, będący aktualizacją opublikowanych w 2016 wytycznych. W dokumencie zawarto dane opublikowane po 2016 roku i zawiera on najnowsze wskazania dotyczące postępowania profilaktycznego w populacji chorych onkologicznych, ze szczególnym uwzględnieniem profilaktyki przeciwzakrzepowej w dyscyplinach zabiegowych. Został ponadto poszerzony o wskazania dotyczące pacjentów poniżej 18. roku życia.
Get Citation

Keywords

żylna choroba zakrzepowo-zatorowa, choroba nowotworowa, leczenie chirurgiczne, profilaktyka przeciwzakrzepowa, terapia przeciwnowotworowa

About this article
Title

Guidelines on the prevention and treatment of venous thromboembolism in cancer patients treated surgically, including patients under 18 years of age

Journal

Acta Angiologica

Issue

Vol 27, No 3 (2021)

Article type

Guidelines / Expert consensus

Pages

81-112

Page views

2656

Article views/downloads

2573

DOI

10.5603/AA.2021.0006

Bibliographic record

Acta Angiologica 2021;27(3):81-112.

Keywords

żylna choroba zakrzepowo-zatorowa
choroba nowotworowa
leczenie chirurgiczne
profilaktyka przeciwzakrzepowa
terapia przeciwnowotworowa

Authors

Zbigniew Krasiński
Tomasz Urbanek
Anetta Undas
Joanna Rupa-Matysek
Aleksander Araszkiewicz
Katarzyna Derwich
Aneta Klotzka
Artur Antoniewicz
Beata Begier-Krasińska
Cezary Piwkowski
Tomasz Banasiewicz
Marcin Gabriel
Piotr Ładziński
Witold Tomkowski
Dawid Murawa
Rodryg Ramlau
Piotr Rutkowski
Piotr Pruszczyk
Filip M. Szymański
Andrzej Szuba
Tomasz Zubilewicz
Stefan Sajdak
Jerzy Windyga

References (191)
  1. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999; 78(5): 285–291.
  2. Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166(4): 458–464.
  3. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5(3): 632–634.
  4. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016; 41(1): 3–14.
  5. Urbanek T, Krasiński Z, Kostrubiec M, et al. Venous thromboembolism prophylaxis in cancer patients — guidelines focus on surgical patients. Acta Angiologica. 2017; 22(3): 71–102.
  6. http://www.g-i-n.net.
  7. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020; 4(19): 4693–4738.
  8. Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019; 3(23): 3898–3944.
  9. Kakkos SK, Gohel M, Baekgaard N, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg. 2021; 61(1): 9–82.
  10. Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020; 38(5): 496–520.
  11. Farge D, Frere C, Connors J, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. The Lancet Oncology. 2019; 20(10): e566–e581.
  12. Shojania KG, Sampson M, Ansari MT, et al. How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med. 2007; 147(4): 224–233.
  13. Wittens C, Davies AH, Bækgaard N, et al. Editor's Choice – Management of Chronic Venous Disease. European Journal of Vascular and Endovascular Surgery. 2015; 49(6): 678–737.
  14. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2): 315–352.
  15. Rabe E, Partsch H, Hafner J, et al. Indications for medical compression stockings in venous and lymphatic disorders: An evidence-based consensus statement. Phlebology. 2018; 33(3): 163–184.
  16. Kahn SR, Comerota AJ, Cushman M, et al. American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014; 130(18): 1636–1661.
  17. Guyatt G, Oxman A, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008; 336(7652): 1049–1051.
  18. Guyatt GH, Oxman AD, Vist GE, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650): 924–926.
  19. Guyatt GH, Norris SL, Schulman S, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): 53S–70S.
  20. Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol. 2014; 8: 129–137.
  21. Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013; 11(1): 56–70.
  22. Lyman GH, Bohlke K, Falanga A, et al. American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015; 11(3): e442–e444.
  23. Mandalà M, Falanga A, Roila F, et al. ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011; 22 Suppl 6: vi85–vi92.
  24. Gould MK, Garcia DA, Wren SM, et al. Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e185S–e194S.
  25. Zawilska K, Bała M, Błędowski P, et al. Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update. Polish Archives of Internal Medicine. 2012; 122(Suppl. 2): 1–76.
  26. Akl EA, Muti P, Schünemann HJ. Anticoagulation in patients with cancer: an overview of reviews. Pol Arch Med Wewn. 2008; 118(4): 183–193.
  27. Kakkar VV, Howe CT, Nicolaides AN, et al. Deep vein thrombosis of the leg. The American Journal of Surgery. 1970; 120(4): 527–530.
  28. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev. 1992; 11(3-4): 237–248.
  29. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015; 12(8): 464–474.
  30. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007; 44(2): 62–69.
  31. Wun T, White RH, Ku GH, et al. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood. 2009; 113(17): 3911–3917.
  32. Pellino G, Sciaudone G, Candilio G, et al. Predictors of Venous Thromboembolism after Colorectal Surgery in a Single Unit. Acta Chir Belg. 2015; 115(4): 288–292.
  33. Kucher N, Spirk D, Baumgartner I, et al. Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Ann Oncol. 2010; 21(5): 931–935.
  34. Lyman GH. Thromboprophylaxis with low-molecular--weight heparin in medical patients with cancer. Cancer. 2009; 115: 5637.
  35. Agnelli G, Caprini JA. The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options. J Surg Oncol. 2007; 96(3): 265–272.
  36. Heit JA, Silverstein MD, Mohr DN. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160(6): 809–815.
  37. Nijziel MR, van Oerle R, Hillen HFP, et al. From Trousseau to angiogenesis: the link between the haemostatic system and cancer. Neth J Med. 2006; 64(11): 403–410.
  38. Easaw JC, Shea-Budgell MA, Wu CMJ, et al. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. Curr Oncol. 2015; 22(2): 133–143.
  39. Caprini JA, Arcelus JI, Hasty JH, et al. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991; 17 Suppl 3: 304–312.
  40. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005; 51(2-3): 70–78.
  41. Ay C, Pabinger I. VTE risk assessment in cancer. Who needs prophylaxis and who does not? Hamostaseologie. 2015; 35(4): 319–324.
  42. Bouras G, Burns EM, Howell AM, et al. Risk of Post-Discharge Venous Thromboembolism and Associated Mortality in General Surgery: A Population-Based Cohort Study Using Linked Hospital and Primary Care Data in England. PLoS One. 2015; 10(12): e0145759.
  43. NICE guidance: Venous thromboembolism: reducing the risk: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital [CG92]. https://www.nice.org.uk/guidance/cg92..
  44. Törngren S, Rieger A. Prophylaxis of deep venous thrombosis in colorectal surgery. Dis Colon Rectum. 1982; 25(6): 563–566.
  45. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl): 338S–400S.
  46. Merkow RP, Bilimoria KY, McCarter MD, et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg. 2011; 254(1): 131–137.
  47. Alsubaie H, Leggett C, Lambert P, et al. Diagnosis of VTE postdischarge for major abdominal and pelvic oncologic surgery: implications for a change in practice. Can J Surg. 2015; 58(5): 305–311.
  48. Larsen AC, Frøkjær JB, Fisker RV, et al. Treatment-related frequency of venous thrombosis in lower esophageal, gastro-esophageal and gastric cancer--a clinical prospective study of outcome and prognostic factors. Thromb Res. 2015; 135(5): 802–808.
  49. Lodders JN, Parmar S, Stienen NLM, et al. Incidence of symptomatic venous thromboembolism in oncological oral and maxillofacial operations: retrospective analysis. Br J Oral Maxillofac Surg. 2015; 53(3): 244–250.
  50. Chiesa Estomba C, Rivera Schmitz T, Ossa Echeverri CC, et al. The risk of venous thromboembolism in ENT and head & neck surgery. Otolaryngol Pol. 2015; 69(3): 31–36.
  51. Kakei Y, Akashi M, Hasegawa T, et al. Incidence of Venous Thromboembolism After Oral Oncologic Surgery With Simultaneous Reconstruction. J Oral Maxillofac Surg. 2016; 74(1): 212–217.
  52. Tran BH, Nguyen TJ, Hwang BH, et al. Risk factors associated with venous thromboembolism in 49,028 mastectomy patients. Breast. 2013; 22(4): 444–448.
  53. De Martino RR, Goodney PP, Spangler EL, et al. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg. 2012; 55(4): 1035–1040.e4.
  54. Lovely JK, Nehring SA, Boughey JC, et al. Balancing venous thromboembolism and hematoma after breast surgery. Ann Surg Oncol. 2012; 19(10): 3230–3235.
  55. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg. 1988; 208(2): 227–240.
  56. Wille-Jorgensen P. Prophylaxis of postoperative deep venous thrombosis. JAMA: The Journal of the American Medical Association. 1985; 253(8): 1120b-1120.
  57. Bergqvist D, Burmark US, Frisell J, et al. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg. 1986; 73(3): 204–208.
  58. Bergqvist D, Mätzsch T, Burmark US, et al. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg. 1988; 75(9): 888–891.
  59. Samama M, Bernard P, Bonnardot JP, et al. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg. 1988; 75(2): 128–131.
  60. Leizorovicz A, Picolet H, Peyrieux JC, et al. Prevention of postoperative deep vein thrombosis in general surgery: a multicenter double-blind study comparing two doses of logiparin and standard heparin. Br J Surg. 1991; 78: 412–416.
  61. Boneu B. An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group. Blood Coagul Fibrinolysis. 1993; 4 Suppl 1: S21–S22.
  62. ENOXACAN Study Group (1997) Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomi¬zed multicentre trial with venographic assessment. Br J Surg; 84: 1099–1103.
  63. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet. 1993; 341(8840): 259–265.
  64. The European Fraxiparin Study (EFS) Group (1988) Compari¬son of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg; 75: 1058–1063.
  65. Baykal C, Al A, Demirtaş E, et al. Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double-blind clinical study. Eur J Gynaecol Oncol. 2001; 22(2): 127–130.
  66. Akl EA, Kahale L, Sperati F, et al. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Cochrane Database Syst Rev. 2014(6): CD009447.
  67. Bergqvist D, Burmark US, Flordal PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. British Journal of Surgery. 2005; 82(4): 496–501.
  68. Kakkar AK, Agnelli G, George D et al (2011) The ultra-low-molecular-weight heparin semuloparin for prevention of venous thromboembolism in patients undergoing major abdominal surgery. Presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego, CA, 2011, December 10–13, 2011 2011.
  69. Simonneau G, Laporte S, Mismetti P, et al. FX140 Study Investigators. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost. 2006; 4(8): 1693–1700.
  70. Agnelli G, Bergqvist D, Cohen AT, et al. PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. 2005; 92(10): 1212–1220.
  71. Yamaoka Y, Ikeda M, Ikenaga M, et al. Safety and efficacy of fondaparinux for prophylaxis of venous thromboembolism after colorectal cancer resection: a propensity score matched analysis. Dig Surg. 2015; 32(3): 190–195.
  72. Yasui M, Ikeda M, Miyake M, et al. Clinical Study Group of Osaka University (CSGO), Colorectal Group. Comparison of bleeding risks related to venous thromboembolism prophylaxis in laparoscopic vs open colorectal cancer surgery: a multicenter study in Japanese patients. Am J Surg. 2017; 213(1): 43–49.
  73. Kimura Y, Oki E, Ando K, et al. Incidence of Venous Thromboembolism Following Laparoscopic Surgery for Gastrointestinal Cancer: A Single-Center, Prospective Cohort Study. World J Surg. 2016; 40(2): 309–314.
  74. Xie YZ, Fang K, Ma WL, et al. Risk of postoperative deep venous thrombosis in patients with colorectal cancer treated with open or laparoscopic colorectal surgery: a meta-analysis. Indian J Cancer. 2015; 51 Suppl 2: e42–e44.
  75. Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Guidelines Committee. Guidelines for deep venous thrombosis prophylaxis during laparoscopic surgery. Surg Endosc. 2007; 21(6): 1007–1009.
  76. Vedovati MC, Becattini C, Rondelli F, et al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg. 2014; 259(4): 665–669.
  77. Fagarasanu A, Alotaibi GS, Hrimiuc R, et al. Role of Extended Thromboprophylaxis After Abdominal and Pelvic Surgery in Cancer Patients: A Systematic Review and Meta-Analysis. Ann Surg Oncol. 2016; 23(5): 1422–1430.
  78. Felder S, Rasmussen MS, King R, et al. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev. 2018; 11: CD004318.
  79. Bustos Merlo AB, Arcelus Mart ınez JI, Turi o Luque JD, et al. Form of presentation, natural history and course of postoperative venous thromboembolism in patients operated on for pelvic and abdominal cancer. Analysis of the RIETE registry. Cir Esp 95: 328-334, 2017.
  80. Guo Q, Huang B, Zhao J, et al. Perioperative Pharmacological Thromboprophylaxis in Patients With Cancer: A Systematic Review and Meta-analysis. Ann Surg. 2017; 265(6): 1087–1093.
  81. Carrier M, Altman AD, Blais N, et al. Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery. Am J Surg. 2019; 218(3): 537–550.
  82. Schomburg J, Krishna S, Soubra A, et al. Extended outpatient chemoprophylaxis reduces venous thromboembolism after radical cystectomy. Urol Oncol. 2018; 36(2): 77.e9–77.e13.
  83. Pariser JJ, Pearce SM, Anderson BB, et al. Extended Duration Enoxaparin Decreases the Rate of Venous Thromboembolic Events after Radical Cystectomy Compared to Inpatient Only Subcutaneous Heparin. J Urol. 2017; 197(2): 302–307.
  84. Kim BJ, Day RW, Davis CH, et al. Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective. J Thromb Haemost. 2017; 15(11): 2158–2164.
  85. Bergqvist D, Agnelli G, Cohen AT, et al. ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002; 346(13): 975–980.
  86. Rasmussen MS, Jorgensen LN, Wille-Jørgensen P, et al. FAME Investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006; 4(11): 2384–2390.
  87. Sakon M, Kobayashi T, Shimazui T. Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study. Thromb Res. 2010; 125(3): e65–e70.
  88. Nagata C, Tanabe H, Takakura S, et al. Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy. J Obstet Gynaecol Res. 2015; 41(9): 1440–1448.
  89. Song KY, Yoo HMo, Kim EY, et al. Optimal prophylactic method of venous thromboembolism for gastrectomy in Korean patients: an interim analysis of prospective randomized trial. Ann Surg Oncol. 2014; 21(13): 4232–4238.
  90. Wang Jp, Lin Yd, Wang L, et al. [Effect of intermittent pneumatic compression on coagulation function and deep venous hemodynamics of lower limbs after rectal cancer resection]. Zhonghua Wei Chang Wai Ke Za Zhi. 2013; 16(8): 739–743.
  91. Ramirez JI, Vassiliu P, Gonzalez-Ruiz C, et al. Sequential compression devices as prophylaxis for venous thromboembolism in high-risk colorectal surgery patients: reconsidering American Society of Colorectal Surgeons parameters. Am Surg. 2003; 69(11): 941–945.
  92. Zareba P, Wu C, Agzarian J, et al. Meta-analysis of randomized trials comparing combined compression and anticoagulation with either modality alone for prevention of venous thromboembolism after surgery. Br J Surg. 2014; 101(9): 1053–1062.
  93. Jung YJu, Seo HoS, Park CH, et al. Venous Thromboembolism Incidence and Prophylaxis Use After Gastrectomy Among Korean Patients With Gastric Adenocarcinoma: The PROTECTOR Randomized Clinical Trial. JAMA Surg. 2018; 153(10): 939–946.
  94. Nagata C, Tanabe H, Takakura S, et al. Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy. J Obstet Gynaecol Res. 2015; 41(9): 1440–1448.
  95. Dong J, Wang J, Feng Y, et al. Effect of low molecular weight heparin on venous thromboembolism disease in thoracotomy patients with cancer. J Thorac Dis. 2018; 10(3): 1850–1856.
  96. Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007; 110(10): 2339–2346.
  97. Vitale C, D'Amato M, Calabrò P, et al. Venous thromboembolism and lung cancer: a review. Multidiscip Respir Med. 2015; 10(1): 28.
  98. Zhang Y, Yang Y, Chen W, et al. China Venous Thromboembolism VTE Study Group, China Venous Thromboembolism (VTE) Study Group. Prevalence and associations of VTE in patients with newly diagnosed lung cancer. Chest. 2014; 146(3): 650–658.
  99. Steuer CE, Behera M, Kim S, et al. Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. Lung Cancer. 2015; 88(1): 80–84.
  100. Yu Y, Lv Q, Zhang B, et al. Adjuvant therapy with heparin in patients with lung cancer without indication for anticoagulants: A systematic review of the literature with meta-analysis. J Cancer Res Ther. 2016; 12(Supplement): 37–42.
  101. Fuentes HE, Oramas DM, Paz LH, et al. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer. Thromb Res. 2017; 154: 28–34.
  102. Hachey KJ, Hewes PD, Porter LP, et al. Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer. J Thorac Cardiovasc Surg. 2016; 151(1): 37–44.e1.
  103. Sterbling HM, Rosen AK, Hachey KJ, et al. Caprini Risk Model Decreases Venous Thromboembolism Rates in Thoracic Surgery Cancer Patients. Ann Thorac Surg. 2018; 105(3): 879–885.
  104. Tun NM, Guevara E, Oo TH. Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Blood Coagul Fibrinolysis. 2016; 27(3): 270–274.
  105. Salmaggi A, Simonetti G, Trevisan E, et al. Perioperative thromboprophylaxis in patients with craniotomy for brain tumours: a systematic review. J Neurooncol. 2013; 113(2): 293–303.
  106. Collen JF, Jackson JL, Shorr AF, et al. Prevention of venous thromboembolism in neurosurgery: a metaanalysis. Chest. 2008; 134(2): 237–249.
  107. Hamilton MG, Yee WH, Hull RD, et al. Venous thromboembolism prophylaxis in patients undergoing cranial neurosurgery: a systematic review and meta-analysis. Neurosurgery. 2011; 68(3): 571–581.
  108. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer. 1997; 33(10): 1592–1596.
  109. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. 2000; 89(3): 640–646, doi: 10.1002/1097-0142(20000801)89:3<640::aid-cncr20>3.0.co;2-e.
  110. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol. 1983; 13(3): 334–336.
  111. Walsh DC, Kakkar AK. Thromboembolism in brain tumors. Curr Opin Pulm Med. 2001; 7(5): 326–331.
  112. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007; 106(4): 601–608.
  113. Jenkins EO, Schiff D, Mackman N, et al. Venous thromboembolism in malignant gliomas. J Thromb Haemost. 2010; 8(2): 221–227.
  114. Yust-Katz S, Mandel JJ, Wu J, et al. Venous thromboembolism (VTE) and glioblastoma. J Neurooncol. 2015; 124(1): 87–94.
  115. Chan AT, Atiemo A, Diran LK, et al. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis. 1999; 8(2): 139–142.
  116. Kimmell KT, Walter KA. Risk factors for venous thromboembolism in patients undergoing craniotomy for neoplastic disease. J Neurooncol. 2014; 120(3): 567–573.
  117. Turpie AG, Gallus A, Beattie WS, et al. Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. Neurology. 1977; 27(5): 435–438.
  118. Skillman JJ, Collins RE, Coe NP, et al. Prevention of deep vein thrombosis in neurosurgical patients: a controlled, randomized trial of external pneumatic compression boots. Surgery. 1978; 83(3): 354–358.
  119. Bucci M, Papadopoulos S, Chen J, et al. Mechanical prophylaxis of venous thrombosis in patients undergoing craniotomy: A randomized trial. Surgical Neurology. 1989; 32(4): 285–288.
  120. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med. 1998; 339(2): 80–85.
  121. Turpie AG, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis in potential neurosurgical patients. A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. Arch Intern Med. 1989; 149(3): 679–681.
  122. Wautrecht JC, Macquaire V, Vandesteene A et al (1996) Prevention of deep vein thrombosis in neurosurgical patients withbrain tumors: a controlled, randomized study comparing graded compression stockings alone and with intermittent sequential compression: correlation with pre- and post-operative fibrinolysis; preliminary results. Int Angiol; 15 (suppl 1): 5–10.
  123. Sobieraj-Teague M, Hirsh J, Yip G, et al. Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high-risk neurosurgical patients. J Thromb Haemost. 2012; 10(2): 229–235.
  124. Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med. 2000; 160(15): 2327–2332.
  125. Khaldi A, Helo N, Schneck MJ, et al. Venous thromboembolism: deep venous thrombosis and pulmonary embolism in a neurosurgical population. J Neurosurg. 2011; 114(1): 40–46.
  126. Dickinson LD, Miller LD, Patel CP, et al. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery. 1998; 43(5): 1074–1081.
  127. Nurmohamed MT, van Riel AM, Henkens CM, et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost. 1996; 75(2): 233–238.
  128. Cerrato D, Ariano C, Fiacchino F. Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. J Neurosurg. 1978; 49(3): 378–381.
  129. Constantini S, Kanner A, Friedman A, et al. Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study. J Neurosurg. 2001; 94(6): 918–921.
  130. Goldhaber SZ, Dunn K, Gerhard-Herman M, et al. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest. 2002; 122(6): 1933–1937.
  131. Macdonald RL, Amidei C, Baron J, et al. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg Neurol. 2003; 59(5): 363–72; discussion 372.
  132. Glotzbecker MP, Bono CM, Wood KB, et al. Thromboembolic disease in spinal surgery: a systematic review. Spine (Phila Pa 1976). 2009; 34(3): 291–303.
  133. Samama CM, Albaladejo P, Benhamou D, et al. Committee for Good Practice Standards of the French Society for Anaesthesiology and Intensive Care (SFAR). Venous thromboembolism prevention in surgery and obstetrics: clinical practice guidelines. Eur J Anaesthesiol. 2006; 23(2): 95–116.
  134. Nicolaides AN, Fareed J, Kakkar AK, et al. Cardiovascular Disease Educational and Research Trust and the International Union of Angiology. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol. 2001; 20(1): 1–37.
  135. Streiff MB, Holmstrom B, Ashrani A, et al. Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. J Natl Compr Canc Netw. 2015; 13(9): 1079–1095.
  136. Forrest JB, Clemens JQ, Finamore P, et al. American Urological Association. AUA Best Practice Statement for the prevention of deep vein thrombosis in patients undergoing urologic surgery. J Urol. 2009; 181(3): 1170–1177.
  137. Colby FH. The prevention of fatal pulmonary emboli after prostatectomy. J Urol. 1948; 59(5): 920–4; Disc., 925.
  138. Gordon-Smith IC, Hickman JA, el-Masri SH. The efect of the fibrinolytic inhibitor epsilonaminocaproic amid on the incidence of deep-vein thrombosis after prostatectomy. Br J Surg. 1972; 59: 599.
  139. Nicolaides AN, Field ES, Kakkar VV, et al. Prostatectomy and deep-vein thrombosis. Br J Surg. 1972; 59(6): 487–488.
  140. Thomas PJ, Nurse DE, Deliveliotis C, et al. Cystoprostatectomy and substitution cystoplasty for locally invasive bladder cancer. Br J Urol. 1992; 70(1): 40–42.
  141. Alberts BD, Woldu SL, Weinberg AC, et al. Venous thromboembolism after major urologic oncology surgery: a focus on the incidence and timing of thromboembolic events after 27,455 operations. Urology. 2014; 84(4): 799–806.
  142. Potretzke AM, Wong KS, Shi F, et al. Highest risk of symptomatic venous thromboembolic events after radical cystectomy occurs in patients with obesity or nonurothelial cancers. Urol Ann. 2015; 7(3): 355–360.
  143. VanDlac AA, Cowan NG, Chen Y, et al. Timing, incidence and risk factors for venous thromboembolism in patients undergoing radical cystectomy for malignancy: a case for extended duration pharmacological prophylaxis. J Urol. 2014; 191(4): 943–947.
  144. Rosario DJ, Becker M, Anderson JB. The changing pattern of mortality and morbidity from radical cystectomy. BJU Int. 2000; 85(4): 427–430.
  145. James AC, Holt SK, Wright JL, et al. Burden and timing of venothrombolic events in patients younger than 65 years undergoing radical cystectomy for bladder cancer. Urol Oncol. 2014; 32(6): 815–819.
  146. White RH, Zhou H, Gage BF, et al. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003; 90(3): 446–455.
  147. Heinzer H, Hammerer P, Graefen M, et al. Thromboembolic complication rate after radical retropubic prostatectomy. Impact of routine ultrasonography for the detection of pelvic lymphoceles and hematomas. Eur Urol. 1998; 33(1): 86–90.
  148. Leibovitch I, Foster R, Wass J, et al. Color Doppler Flow Imaging For Deep Venous Thrombosis Screening in Patients Undergoing Pelvic Lymphadenectomy and Radical Retropubic Prostatectomy for Prostatic Carcinoma. The Journal of Urology. 1995: 1866–1869.
  149. Hautmann RE, Sauter TW, Wenderoth UK. Radical retropubic prostatectomy: Morbidity and urinary continence in 418 consecutive cases. Urology. 1994; 43: 47–51.
  150. Leandri P, Rossignol G, Gautier JR, et al. Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases. J Urol. 1992; 147(3 Pt 2): 883–887.
  151. Pedersen K, Herder A. Radical Retropubic Prostatectomy for Localised Prostatic Carcinoma: A Clinical and Pathological Study of 201 Cases. Scand J Urol Nephrol. 1993; 27(2): 219–224.
  152. Shekarriz B, Upadhyay J, Wood DP. Intraoperative, perioperative, and long-term complications of radical prostatectomy. Urol Clin North Am. 2001; 28(3): 639–643.
  153. Andriole GL, Smith DS, Rao G, et al. Early complications of contemporary anatomical radical retropubic prostatectomy. J Urol. 1994; 152(5 Pt 2): 1858–1860.
  154. Dillioglugil O, Leibman BD, Leibman NS, et al. Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol. 1997; 157(5): 1760–1767.
  155. Lerner SE, Blute ML, Lieber MM, et al. Morbidity of contemporary radical retropubic prostatectomy for localized prostate cancer. Oncology (Williston Park). 1995; 9(5): 379–82; discussion 382, 385.
  156. Catalona WJ, Carvalhal GF, Mager DE, et al. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol. 1999; 162(2): 433–438.
  157. Hammond J, Kozma C, Hart JC, et al. Rates of venous thromboembolism among patients with major surgery for cancer. Ann Surg Oncol. 2011; 18(12): 3240–3247.
  158. Beyer J, Wessela S, Hakenberg OW, et al. Incidence, risk profile and morphological pattern of venous thromboembolism after prostate cancer surgery. J Thromb Haemost. 2009; 7(4): 597–604.
  159. Chan SYS, Leung VFY, Yee CH, et al. Incidence of postoperative deep vein thrombosis after robotic-assisted laparoscopic prostatectomy: a prospective study in Chinese patients. Int Urol Nephrol. 2014; 46(11): 2139–2142.
  160. Streiff MB, Bockenstedt PL, Cataland SR, et al. National comprehensive cancer network. Venous thromboembolic disease. J Natl Compr Canc Netw. 2013; 11(11): 1402–1429.
  161. Pettus JA, Eggener SE, Shabsigh A, et al. Perioperative clinical thromboembolic events after radical or partial nephrectomy. Urology. 2006; 68(5): 988–992.
  162. Smith AB, Horvath-Puhó E, Nielsen ME, et al. Effect of comorbidity on risk of venous thromboembolism in patients with renal cell carcinoma. Urol Oncol. 2014; 32(4): 466–472.
  163. Ihaddadene R, Yokom DW, Le Gal G, et al. The risk of venous thromboembolism in renal cell carcinoma patients with residual tumor thrombus. J Thromb Haemost. 2014; 12(6): 855–859.
  164. Yokom DW, Ihaddadene R, Moretto P, et al. Increased risk of preoperative venous thromboembolism in patients with renal cell carcinoma and tumor thrombus. J Thromb Haemost. 2014; 12(2): 169–171.
  165. Kavoussi L, Sosa E, Chandhoke P, et al. Complications of Laparoscopic Pelvic Lymph Node Dissection. Journal of Urology. 1993; 149(2): 322–325.
  166. Caddedu JA, Wolf JS, Nakada S. Complications of laparoscopic procedures after concentrated training in urological laparoscopy. J Urol. 2001; 166: 2109–2111.
  167. Fahlenkamp D, Rassweiler J, Fornara P, et al. Complications of laparoscopic procedures in urology: experience with 2,407 procedures at 4 German centers. J Urol. 1999; 162(3 Pt 1): 765–70; discussion 770.
  168. Rassweiler JJ, Seemann O, Frede T, et al. Retroperitoneoscopy: experience with 200 cases. J Urol. 1998; 160(4): 1265–1269.
  169. Trabulsi EJ, Guillonneau B, Touijer K, et al. Laparoscopic radical prostatectomy: a review of techniques and results worldwide. Minerva Urol Nefrol. 2003; 55(4): 239–250.
  170. Montgomery JS, Wolf JS. Venous thrombosis prophylaxis for urological laparoscopy: fractionated heparin versus sequential compression devices. J Urol. 2005; 173(5): 1623–1626.
  171. Permpongkosol S, Link RE, Su LM, et al. Complications of 2,775 urological laparoscopic procedures: 1993 to 2005. J Urol. 2007; 177(2): 580–585.
  172. Secin FP, Jiborn T, Bjartell AS, et al. Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. Eur Urol. 2008; 53(1): 134–145.
  173. Chalmers D, Scarpato K, Staff I, et al. Does Heparin Prophylaxis Reduce the Risk of Venous Thromboembolism in Patients Undergoing Robot-Assisted Prostatectomy? Journal of Endourology. 2013; 27(6): 800–803.
  174. Patel T, Kirby W, Hruby G, et al. Heparin prophylaxis and the risk of venous thromboembolism after robotic-assisted laparoscopic prostatectomy. BJU Int. 2011; 108(5): 729–732.
  175. Abel EJ, Wong K, Sado M, et al. Surgical operative time increases the risk of deep venous thrombosis and pulmonary embolism in robotic prostatectomy. JSLS. 2014; 18(2): 282–287.
  176. Donat R, Mancey-Jones B. Incidence of thromboembolism after transurethral resection of the prostate (TURP)--a study on TED stocking prophylaxis and literature review. Scand J Urol Nephrol. 2002; 36(2): 119–123.
  177. Kibel A, Loughlin K. Pathogenesis and Prophylaxis of Postoperative Thromboembolic Disease in Urological Pelvic Surgery. The Journal of Urology. 1995: 1763–1774.
  178. Tikkinen KAO, Agarwal A, Craigie S, et al. Systematic reviews of observational studies of risk of thrombosis and bleeding in urological surgery (ROTBUS): introduction and methodology. Syst Rev. 2014; 3: 150.
  179. Kutnowski M, Vandendris M, Steinberger R, et al. Prevention of postoperative deep-vein thrombosis by low-dose heparin in urological surgery. A double-blind, randomised study. Urol Res. 1977; 5(3): 123–125.
  180. Sebeseri O, Kummer H, Zingg E. Controlled prevention of post-operative thrombosis in urological diseases with depot heparin. Eur Urol. 1975; 1(5): 229–230.
  181. Bigg SW, Catalona WJ. Prophylactic mini-dose heparin in patients undergoing radical retropubic prostatectomy. A prospective trial. Urology. 1992; 39(4): 309–313.
  182. Vandendris M, Kutnowski M, Futeral B, et al. Prevention of postoperative deep-vein thrombosis by low-dose heparin in open prostatectomy. Urol Res. 1980; 8(4): 219–221.
  183. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988; 318(18): 1162–1173.
  184. Nakamura K, Kasraeian A, Yacoub S, et al. The use of enoxaparin to prevent venous thromboembolism in patients undergoing radical retropubic prostatectomy: feasibility and utility. Int Braz J Urol. 2007; 33(3): 347–52; discussion 352.
  185. Grasso M, Confalonieri S, Blanco S, et al. Preoperative blood donation program and postoperative low molecular weight heparine (LMWH) prophylaxis in patients undergoing radical prostatectomy. Arch Esp Urol. 2009; 62(2): 161–166.
  186. Donat R, Mancey-Jones B. Incidence of thromboembolism after transurethral resection of the prostate (TURP)--a study on TED stocking prophylaxis and literature review. Scand J Urol Nephrol. 2002; 36(2): 119–123.
  187. Scarpa RM, Carrieri G, Gussoni G, et al. @RISTOS Study Group. Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS Study. Eur Urol. 2007; 51(1): 130–5; discussion 136.
  188. Cerruto MA, D'Elia C, Piccoli M, et al. Association between postoperative thromboembolism prophylaxis and complications following urological surgery. Exp Ther Med. 2016; 11(1): 157–163.
  189. Coe NP, Collins RE, Klein LA, et al. Prevention of deep vein thrombosis in urological patients: a controlled, randomized trial of low-dose heparin and external pneumatic compression boots. Surgery. 1978; 83(2): 230–234.
  190. Koya MP, Manoharan M, Kim SS, et al. Venous thromboembolism in radical prostatectomy: is heparinoid prophylaxis warranted? BJU Int. 2005; 96(7): 1019–1021.
  191. Cisek LJ, Walsh PC. Thromboembolic complications following radical retropubic prostatectomy. Influence of external sequential pneumatic compression devices. Urology. 1993; 42(4): 406–408.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl